Aktuelle Aspekte zur supportiven und adjuvanten Therapie der Sepsis

Zusammenfassung

Sepsis ist definiert als eine systemische Entzündungsreaktion auf dem Boden eines infektiösen Fokus. Diese systemische Entzündungsreaktion ist mit der Ausschüttung multipler Zytokine vergesellschaftet. Eine Reihe von antiinflammatorisch wirksamen Substanzen wurde daher in den letzten Jahren in ihrer Wirkung auf die Mortalität von Patienten mit Sepsis untersucht. Lediglich niedrig dosiertes Hydrokortison und rekombinantes humanes aktiviertes Protein C konnten in kontrollierten Studien mit hoher Fallzahl eine Prognoseverbesserung gegenüber der Kontrollgruppe erzielen. Auch das TNF-α-Antikörperfragment Afelimomab zeigte eine Letalitätssenkung, steht aber nicht als Medikament zur Verfügung. Für Ibuprofen, Interleukin-1-Rezeptor-Antagonisten und lösliche TNF-α-Rezeptoren sowie eine hoch dosierte Kortikosteroid- oder Antithrombin-III-Behandlung als antiinflammatorische bzw. antikoagulatorische Therapie in der Sepsis gibt es momentan keine wissenschaftlich eindeutig gesicherte Indikation. Vor der adjuvanten antiinflammatorischen Therapie steht in jedem Falle die Kontrolle des Infektionsfokus sowie eine aggressive Kreislaufstabilisierung.

Abstract

Sepsis is defined as a systemic inflammatory response to an infection. This systemic inflammatory response is associated with release of multiple cytokines. During the last years, several antiinflammatory and anticoagulatory substances had been investigated regarding their effects on mortality in patients with sepsis. However, only low-dose hydrocortisone and the recombinant human activated protein C were capable in improving the outcome in controlled studies with large sample size. The antibody fragment of the TNF-α binding antibody afelimomab also reduced sepsis mortality but is not available as a licensed drug. Ibuprofen, interleukin-1 receptor antagonists and soluble TNF-α-receptors as well as high dosages of corticosteroids do not have a place in the adjunctive treatment of sepsis. Clear data about the usefulness of antithrombin III are missing. Beside the antiinflammatory treatment, the control of the infectious focus and an aggressive hemodynamic stabilization must not be neglected.

Sepsis - Prognose - Kreislaufstabilisierung - adjuvante Therapien - aktiviertes Protein C

Sepsis - outcome - circulatory support - adjuvant therapies - activated protein C

Literatur

• 1 ACCP/SCCM Consensus Conference Committee . Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.  Crit Care Med. 1992;  20 (6) 864-874
• 2 International Sepsis Forum . Guidelines for the management of severe sepsis and septic shock.  Intensive Care Med. 2001;  27, Suppl 1 S1-134
• 3 Meier-Hellmann A. Hämodynamische Stabilisierung in der Sepsis.  Anästhesiologie & Intensivmedizin. 2000;  41 601-613
• 4 Rivers E, Nguyen B. et al . Early goal-directed therapy in the treatment of severe sepsis and septic shock.  N Engl J Med. 2001;  345 1368-1377
• 5 Briegel J, Kellermann W. et al . Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group.  Clin Investig. 1994;  72 782-787
• 6 The Veterans Administration Systemic Sepsis Cooperative Study Group . Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis.  N Engl J Med. 1987;  317 659-665
• 7 Bone R C, Fisher C J. et al . A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock.  N Engl J Med. 1987;  317 653-658
• 8 Lefering R, Neugebauer E A. Steroid controversy in sepsis and septic shock: a meta-analysis.  Crit Care Med. 1995;  23 1294-1303
• 9 Cronin L, Cook D J. et al . Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.  Crit Care Med. 1995;  23 1430-1439
• 10 Loisa P, Rinne T, Kaukinen S. Adrenocortical function and multiple organ failure in severe sepsis.  Acta Anaesthesiol Scand. 2002;  46 145-151
• 11 Annane D, Sebille V. et al . A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin.  JAMA. 2000;  283 1038-1045
• 12 Annane D, Sebille V. et al . Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.  JAMA. 2002;  288 862-871
• 13 Johnson K, Aarden L. et al . The proinflammatory cytokine response to coagulation and endotoxin in whole blood.  Blood. 1996;  87 5051-5060
• 14 Hesselvik J F, Malm J. et al . Protein C, protein S and C4b-binding protein in severe infection and septic shock.  Thromb Haemost. 1991;  65 126-129
• 15 Yan S B, Helterbrand J D. et al . Low levels of protein C are associated with poor outcome in severe sepsis.  Chest. 2001;  120 915-922
• 16 Schmidt-Supprian M, Murphy C. et al . Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes.  Eur Cytokine Netw. 2000;  11 407-413
• 17 Joyce D E, Grinnell B W. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB.  Crit Care Med. 2002;  30 S288-293
• 18 Bernard G R, Vincent J L. et al . Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344 699-709
• 19 Massignon D, Lepape A. et al . Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state.  Haemostasis. 1994;  24 36-48
• 20 Inthorn D, Hoffmann J N. et al . Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis.  Shock. 1998;  10 90-96
• 21 Warren B L, Eid A. et al . Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286 1869-1878
• 22 Abraham E, Wunderink R. et al . Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.  JAMA. 1995;  273 934-941
• 23 Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.  Crit Care Med. 1996;  24 1431-1440
• 24 Marshall J C. Clinical trials of mediator-directed therapy in sepsis: what have we learned?.  Intensive Care Med. 2000;  26 S75-S83
• 25 Reinhart K, Wiegand-Lohnert C. et al . Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.  Crit Care Med. 1996;  24 733-742
• 26 Gallagher J, Fisher C. et al . A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome.  Intensive Care Med. 2001;  27 1169-1178
• 27 Reinhart K, Menges T. et al . Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.  Crit Care Med. 2001;  29 765-769
• 28 Panacek E A, Marshall J. et al . Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: Results of the MONARCS trial.  Chest. 2000;  118 (Suppl) S88
• 29 Bernard G R, Wheeler A P. et al . The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group.  N Engl J Med. 1997;  336 912-918
• 30 Arons M M, Wheeler A P. et al . Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group.  Crit Care Med. 1999;  27 699-707
• 31 Fisher C J, Dhainaut J F. et al . Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.  JAMA. 1994;  271 1836-1843
• 32 Opal S M, Fisher C J. et al . Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.  Crit Care Med. 1997;  25 1115-1124
• 33 Abraham E, Glauser M P. et al . p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.  JAMA. 1997;  277 1531-1538
• 34 Abraham E, Laterre P F. et al . Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.  Crit Care Med. 2001;  29 503-510